Trastuzumab Plus Gemcitabine-Cisplatin for Treatment-Naïve Human Epidermal Growth Factor Receptor 2–Positive Biliary Tract Adenocarcinoma: A Multicenter, Open-Label, Phase II Study (TAB) Patients were ...
HERTHENA-Lung01, a Phase II Trial of Patritumab Deruxtecan (HER3-DXd) in Epidermal Growth Factor Receptor–Mutated Non–Small-Cell Lung Cancer After Epidermal Growth Factor Receptor Tyrosine Kinase ...
PHILADELPHIA, June 29, 2021 /PRNewswire/ — Signant Health, the leader in evidence generation for modern clinical trials, today announced a new acceleration program that reduces study setup timelines ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results